Login
Novavax NASDAQ: NVAX
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants
| Name | Novavax |
| Ticker | NVAX |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 81.33 |
| 52W Low/High | 3.69 / 178.51 |
| Market cap | 4.7 B |
| 1Y Total Return |
1,707.33%
Strong |
| 1Y Volatility |
150.33%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants
Details
| Ticker | NVAX |
| Name | Novavax |
| ISIN | US6700024010 |
| CUSIP | 670002401 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 10/28/20
| Close Price | 81.33 |
| 52W Low/High | 3.69 / 178.51 |
| Market cap | 4.7 B |
| 1Y Total Return |
1,707.33%
Strong |
| 1Y Volatility |
150.33%
High Risk |
| Beta | -0.21 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -185.6% |
| Cash from Op. / Cur. Liabilities | 0.17 |
| Diluted Earnings / Share | -2.70 |
| ROE | - |
| ROIC | -62.0% |
| Price / Revenue | 94.9 |
| Price / Book | 25.8 |
| Price / CF | 130.5 |
| Current Ratio | 3.0 |
| Cur.Liabilities / Tot.Liabilities | 0.4 |
| Financial Leverage | 1.74 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
50
|
21
|
39
|
21
|
19
|
39
|
|
| Gross Profit |
50
|
21
|
39
|
21
|
19
|
27
|
|
| R&D |
100
|
151
|
181
|
181
|
240
|
101
|
|
| EBITDA |
-76
|
-155
|
-163
|
-189
|
-255
|
-91
|
|
| Operating Income |
-84
|
-165
|
-175
|
-200
|
-264
|
-97
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
59
|
23
|
19
|
14
|
14
|
13
|
|
| EPS exc. Extra |
-2.70
|
-8.70
|
-11.33
|
-15.40
|
-20.00
|
-8.00
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
932
|
189
|
286
|
356
|
525
|
425
|
|
| Cash, Eq & Invt ShortTerm |
609
|
78
|
178
|
235
|
401
|
315
|
|
| Total Current Assets |
636
|
110
|
194
|
237
|
420
|
333
|
|
| Total Non-Current Assets |
296
|
79
|
91
|
119
|
105
|
92
|
|
| Intangibles |
124
|
57
|
59
|
62
|
63
|
65
|
|
| Total Liabilities |
548
|
375
|
374
|
415
|
415
|
37
|
|
| Total Current Liabilities |
213
|
41
|
43
|
67
|
82
|
27
|
|
| Long Term Debt |
335
|
333
|
330
|
348
|
333
|
10
|
|
| Shareholder equity |
185
|
-185
|
-88
|
-59
|
110
|
388
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
37
|
-159
|
-194
|
-184
|
-215
|
-78
|
|
| Depreciation |
4
|
8
|
10
|
9
|
7
|
5
|
|
| Cash from Investing |
-228
|
77
|
31
|
156
|
-150
|
-58
|
|
| Capex |
4
|
2
|
2
|
9
|
20
|
15
|
|
| Cash from Financing |
645
|
61
|
139
|
25
|
287
|
200
|
|
| Stock Issued |
445
|
61
|
139
|
25
|
12
|
201
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
324
|
-1
|
|
| Free Cash Flow |
8
|
-77
|
-160
|
-48
|
-341
|
-193
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
3.0
|
2.7
|
4.5
|
3.5
|
5.1
|
12.3
|
|
| Financial Leverage D/E |
1.74
|
-
|
-
|
-
|
2.87
|
0.00
|
|
| Return on Capital Avg |
-62.0%
|
-153.2%
|
-111.6%
|
-81.6%
|
-95.6%
|
-45.8%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available